Catherine Blish

Aditxt Launches High-Sensitivity Neutralizing Antibody Test to Detect Individual Immune Response to COVID-19

Retrieved on: 
Monday, July 12, 2021
Infectious diseases, Biotechnology, Health, Medical specialties, Branches of biology, Medicine, COVID-19, Occupational safety and health, Public health, Zoonoses, Antibody, Neutralizing antibody, Vaccine, COVID-19 testing, Catherine Blish

A multi-dimensional immune response test that tracks multiple combinations of antibody responses against several different antigens, AditxtScore for COVID-19 has been enhanced to include a high-sensitivity neutralizing antibody diagnostic, which makes it possible to assess the strength of an individuals immune response to the SARS-CoV-2 virus.

Key Points: 
  • A multi-dimensional immune response test that tracks multiple combinations of antibody responses against several different antigens, AditxtScore for COVID-19 has been enhanced to include a high-sensitivity neutralizing antibody diagnostic, which makes it possible to assess the strength of an individuals immune response to the SARS-CoV-2 virus.
  • We believe that as more people become vaccinated or exposed to the virus, AditxtScore for COVID-19 with neutralizing antibody diagnostics adds that next level of precision, delivering more detailed information of the strength of immune response against the virus.
  • This multi-multiplex approach to capturing the full spectrum of biomarkers associated with SARS-CoV-2 delivers a highly detailed snapshot of an individuals immune response in a single test cycle.
  • Aditxt is developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming.

Stanford’s Dr. Catherine Blish Joins Deepcell’s Advisory Board

Retrieved on: 
Tuesday, March 2, 2021
Other Health, General Health, Pharmaceutical, Hardware, Oncology, Medical devices, Technology, Clinical trials, Nanotechnology, Biotechnology, Stem cells, Health, Cell biologists, Branches of biology, Catherine Blish, BioHub, California, Mark Zuckerberg, Translational research, Biology, Stanford University

Deepcell, a life science company pioneering AI-powered cell classification and isolation for cell biology and translational research, today announced that Dr. Catherine Blish, MD, PhD , of Stanford University has joined Deepcells Advisory Board, which is composed of world-renowned experts in biology and life science.

Key Points: 
  • Deepcell, a life science company pioneering AI-powered cell classification and isolation for cell biology and translational research, today announced that Dr. Catherine Blish, MD, PhD , of Stanford University has joined Deepcells Advisory Board, which is composed of world-renowned experts in biology and life science.
  • Joining Deepcells Advisory Board provides an opportunity to help the companys leadership team and the scientific community explore the broad uses of Deepcells technology as a tool for new discoveries, interdisciplinary research, and clinically relevant findings.
  • Dr. Blish is also a Fellow at the Stanford Center for Innovation in Global Health and an Investigator of the Chan Zuckerberg Biohub.
  • I am pleased to welcome Dr. Blish to our Advisory Board, said Maddison Masaeli, co-founder and CEO of Deepcell.